Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer

Table 2 Correlation between SSTR expression and clinicopathology in colorectal cancer n (%)

Clinico-pathological factor		n	SSTR1	SSTR2	SSTR3	SSTR4	SSTR5
Sex	Male	73	47(64.4)	26(35.6)	13(17.8)	13(17.8)	28(38.4)
	Female	54	35(64.8)	20(37.0)	11(20.4)	11(20.4)	21(38.9)
Age (yr)	< 60	66	45(68.2)	20(30.3)	12(18.2)	12(18.2)	24(36.4)
	≥ 60	61	37(60.7)	26(42.6)	12(19.7)	12(19.7)	25(41.0)
Tumor site	Right colon	31	18(58.1)	11(35.5)	7(22.6)	6(19.4)	11(35.5)
	Left colon	27	17(63.0)	12(44.4)	5(18.5)	6(22.2)	13(48.1)
	Rectum	69	47(68.1)	23(33.3)	12(17.4)	12(17.4)	25(36.2)
Macroscopic type	Elevated	40	27(67.5)	17(42.5)	10(25.0)	9(22.5)	17(42.5)
	Ulcerative	59	37(62.7)	13(22.0)a	8(13.6)	8(13.6)	21(35.6)
	Infiltrative	28	18(64.3)	16(57.1)	6(21.4)	7(25.0)	11(39.3)
Differentiation	Moderate to well	102	70(68.6)	43(42.2)a	22(21.6)	24(23.5)a	46(45.1)a
	Poor	25	12(48.0)	3(12.0)	2(8.0)	0(0.0)	3(12.0)
Tumor depth	Muscularis	24	14(58.3)	11(45.8)	5(20.8)	3(12.5)	9(37.5)
	Serosa	103	68(66.0)	35(34.0)	19(18.4)	21(20.4)	40(38.8)
Lymph node metastasis	(+)	72	52(72.2)a	24(33.3)	12(16.7)	15(20.8)	26(36.1)
	(-)	55	30(54.5)	22(40.0)	12(21.8)	9(16.4)	23(41.8)
Distant metastasis	(+)	20	15(75.0)	6(30.0)	3(15.0)	2(10.0)	7(35.0)
	(-)	107	67(62.6)	40(37.4)	21(19.6)	22(20.6)	42(39.3)
Dukes’ stage	A	13	7(53.8)	5(38.5)	4(30.8)	2(15.4)	6(46.2)
	B	40	22(55.0)	16(40.0)	8(20.0)	7(17.5)	16(40.0)
	C	54	38(70.4)	19(35.2)	9(16.7)	13(24.1)	20(37.0)

^aP < 0.05.